|
 Speaking before the Senate Special Committee on Aging, Ackman
revealed that Valeant's board will hold a conference call on
Thursday to discuss the costs of heart medications Isuprel and
Nitropress, as well as Cuprimine and Syprine, two drugs that are
used to treat a genetic disorder that causes copper to build up in
the body's organs.
Valeant raised the price of Isuprel by about 720 percent and
Nitropress by 310 percent, after acquiring them in 2015. The other
two were raised by 5,878 percent and 3,162 percent, respectively.
"My recommendation is going to be to reduce the prices," Ackman
testified.
The Senate Special Committee on Aging is one of two U.S.
congressional panels investigating sky-rocketing price increases of
certain decades-old drugs acquired by companies including Valeant
and Turing Pharmaceuticals, a company founded by Martin Shkreli.
Ackman, a major Valeant shareholder, appeared Wednesday alongside
the company's outgoing Chief Executive Michael Pearson and Howard
Schiller, a board member and former chief financial officer.
Ackman joined the board last month as Valeant faced mounting
scrutiny by members of Congress, prosecutors and regulators over its
drug pricing, business practices and accounting - issues that have
caused its share price to plummet almost 90 percent since August.
Valeant has about $30 billion of debt and has been negotiating with
creditors, some of whom issued notices of default after it missed a
deadline for the filing of its financial results.
Ackman said Wednesday that one of his top priorities is to protect
the company from bankruptcy. Later, in response to a question from
Reuters, he expressed confidence that the company will recover.
“There is not going to be any bankruptcy of Valeant,” he said. “We
were in a death spiral, and we have taken steps to deal with the
banks. We are going to file our 10K on time. We brought in a new
CEO.”
Pearson, Ackman and Schiller all told lawmakers on Wednesday they
regretted Valeant's pricing decisions.
"The company was too aggressive and I, as its leader, was too
aggressive in pursuing price increases on certain drugs," he said.
But many lawmakers on the panel appeared skeptical. They questioned
Valeant's business model of investing little in research and
development, and the company's practice of acquiring decades-old
drugs and raising the prices.
Senator Claire McCaskill, the panel's top Democrat, angrily asked
each of the panelists at one point if they could recall one drug
that Valeant didn't raise the price on.
[to top of second column] |
"Not in the United States," Pearson responded, while Schiller was
only able to come up with the name of one drug Valeant acquired
after its purchase of Salix.
"That is not social good, that is social bad," McCaskill said.
Lawmakers also questioned whether Valeant's patient assistance and
rebate programs are truly helping patients and hospitals afford the
medications.
Senator Susan Collins, the panel's chairman, said her committee's
investigation has thus far been unable to find a single hospital
that has received a discount.
"I can assure you that many of the large hospital systems are
getting discounts on the heart drugs," Pearson said.
Pearson is expected to step down in the coming weeks to make way for
the incoming CEO, Joseph Papa, previously of Perrigo Company.
Wednesday's hearing also featured testimony from doctors and a
patient with Wilson's Disease who was forced to stop using Syprine
because of the price spike.
Dr. Frederick Askari of the University of Michigan told the panel
that the cost of Syprine is now so high that it has become less
expensive to get a liver transplant and a life-time supply of
anti-rejection medications.
The patient, Berna Heyman, testified that Valeant refused to help
her when she called to complain about the prices. Later, after
speaking with the media, the company changed its tune, offered to
help, and even sent flowers.
"I refused the flowers," she said.
(Reporting by Sarah N. Lynch in Washington and Bill Berkrot in New
York; Editing by Bernard Orr and Alan Crosby)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
